 Connection
Hitoshi Irabu to Infliximab
This is a "connection" page, showing publications Hitoshi Irabu has written about Infliximab.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.254 |
|
|
|
-
Ishikawa T, Nishimura K, Okamoto N, Akamine K, Inoue N, Irabu H, Kato K, Keino H, Kojima M, Kubo H, Maruyama K, Mizuta M, Shabana K, Shimizu M, Sugita Y, Takakuwa Y, Takanashi S, Takase H, Umebayashi H, Umezawa N, Yamanishi S, Yamazaki K, Yashiro M, Yasumi T, Mori M. Efficacy and safety of tumor necrosis factor inhibitors for systemic juvenile idiopathic arthritis: A systematic review. Mod Rheumatol. 2024 Dec 25; 35(1):174-184.
Score: 0.211
-
Yamaguchi Y, Takasawa K, Irabu H, Hiratoko K, Ichigi Y, Hirata K, Tamura Y, Murakoshi M, Yamashita M, Nakatani H, Shimoda M, Ishii T, Udagawa T, Shimizu M, Kanegane H, Morio T. Infliximab treatment for refractory COVID-19-associated multisystem inflammatory syndrome in a Japanese child. J Infect Chemother. 2022 Jun; 28(6):814-818.
Score: 0.043
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|